ユーイング肉腫市場 - 市場の洞察、疫学、市場予測：2032年

主要7ヶ国におけるユーイング肉腫の総市場規模は、2022年に約2,600万米ドルとなりました。同市場は、予測期間中（2023年～2032年）に拡大すると予測されています。欧州4ヶ国のうち、2022年の市場規模はドイツが最大で、イタリアは最下位となっています。日本では、Seclidemstat+TCが2L+の新興治療薬の中で最も高い市場シェアを獲得すると予想されます。2022年には、米国が主要7ヶ国市場全体の最大シェア（53％）を占め、欧州4ヶ国、英国がこれに続きます。

ユーイング肉腫は、通常、骨の中で増殖を開始するがん性腫瘍です。主に小児や若年成人に発生し、10歳代で発症することが多いものです。ユーイング肉腫はどの骨にも発生しますが、通常は大腿骨、脛骨、上腕骨などに発生します。骨盤の骨もしばしば侵されます。時には、腫瘍が筋肉や軟部組織から始まることもあります。最も一般的な症状は、骨や骨周囲の組織のこわばり、痛み、腫れ、圧痛です。

主要7ヶ国でユーイング肉腫の偶発症例が最も多かったのは米国で、次いで欧州4ヶ国と英国でした。欧州4ヶ国の中ではドイツが最も多く、次いでフランスとなりましたが、イタリアは最も低くなっています。

ユーイング肉腫の治療には一般的に、手術、化学療法、放射線療法を含む集学的アプローチが用いられます。NCCNは、限局性および転移性ユーイング肉腫の治療に対して異なる化学療法の組み合わせを推奨しています。VDC/IE（ビンクリスチン、ドキソルビシン、シクロホスファミドとイホスファミド、エトポシドの交互投与）、VAIA（ビンクリスチン、ドキソルビシン、イホスファミド、ダクチノマイシン）、VIDE（ビンクリスチン、イホスファミド、ドキソルビシン、エトポシド）は、NCCNにより初回治療および転移性疾患の一次治療として推奨されています。二次治療では、シクロホスファミド＋トポテカン、イリノテカン＋テモゾロミド±、シクロホスファミド＋トポテカン、イリノテカン＋テモゾロミド±が推奨されます。

当レポートでは、主要7ヶ国におけるユーイング肉腫市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 主要な洞察

第2章 レポートのイントロダクション

第3章 ユーイング肉腫に関するエグゼクティブサマリー

第4章 主要な出来事

第5章 疫学と市場予測調査手法

第6章 ユーイング肉腫市場概要

• 2019年の治療法別市場シェア（%）分布
• 2032年の治療法別市場シェア（%）分布

第7章 病気の背景と概要

• イントロダクション
• 原因
• 兆候と症状
• 病期
• 危険因子
• 病理学的診断
• 診断テスト

第8章 ユーイング肉腫の治療管理

• 治療アルゴリズム

第9章 ユーイング肉腫の治療ガイドライン

第10章 疫学と患者人口

• 主な調査結果
• 仮定と根拠
• 主要7ヶ国におけるユーイング肉腫の総発生件数
• 米国
• 欧州4ヶ国と英国
• 日本

第11章 患者動向

第12章 ユーイング肉腫の主要エンドポイント

第13章 新興薬剤

第14章 ユーイング肉腫：主要7ヶ国市場分析

• 主な調査結果
• 市場の見通し
• 主要な市場予測の前提条件
• コンジョイント分析
• 主要7ヶ国におけるユーイング肉腫の総市場規模
• 主要7ヶ国における治療法別のユーイング肉腫の市場規模
• 米国における市場規模
• 欧州4ヶ国と英国における市場規模
• 日本における市場規模

第15章 アンメットニーズ

第16章 SWOT分析

第17章 コルの見解

第18章 市場アクセスと償還

• 米国
• 欧州4ヶ国と英国
• 日本

第19章 付録

第20章 DEVEINSIGHTの機能

第21章 免責事項

List of Tables

TABLE 1: SUMMARY OF EWING SARCOMA MARKET AND EPIDEMIOLOGY (2019-2032)

TABLE 2: NCCN RECOMMENDED EWING SARCOMA CHEMOTHERAPY REGIMEN

TABLE 3: TOTAL INCIDENT CASES OF EWING SARCOMA IN THE 7MM (2019-2032)

TABLE 4: TOTAL INCIDENT CASES OF EWING SARCOMA IN THE US (2019-2032)

TABLE 5: AGE-SPECIFIC CASES OF EWING SARCOMA IN THE US (2019-2032)

TABLE 6: GENDER-SPECIFIC CASES OF EWING SARCOMA IN THE US (2019-2032)

TABLE 7: STAGE-SPECIFIC CASES OF EWING SARCOMA IN THE US (2019-2032)

TABLE 8: TOTAL INCIDENT CASES OF EWING SARCOMA IN EU4 AND THE UK (2019-2032)

TABLE 9: AGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2019-2032)

TABLE 10: GENDER-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2019-2032)

TABLE 11: STAGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2019-2032)

TABLE 12: TOTAL INCIDENT CASES OF EWING SARCOMA IN JAPAN (2019-2032)

TABLE 13: AGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2019-2032)

TABLE 14: GENDER-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2019-2032)

TABLE 15: STAGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2019-2032)

TABLE 16: COMPARISON OF EMERGING DRUGS

TABLE 17: SECLIDEMSTAT, CLINICAL TRIAL DESCRIPTION, 2023

TABLE 18: ZEPZELCA, CLINICAL TRIAL DESCRIPTION, 2023

TABLE 19: VERZENIO, CLINICAL TRIAL DESCRIPTION, 2023

TABLE 20: IBRANCE, CLINICAL TRIAL DESCRIPTION, 2023

TABLE 21: MECBOTAMAB VEDOTIN, CLINICAL TRIAL DESCRIPTION, 2023

TABLE 22: IOPOFOSINE I 131, CLINICAL TRIAL DESCRIPTION, 2023

TABLE 23: TP-1287, CLINICAL TRIAL DESCRIPTION, 2023

TABLE 24: INBRX-109, CLINICAL TRIAL DESCRIPTION, 2023

TABLE 25: KEY MARKET FORECAST ASSUMPTION OF EWING SARCOMA IN THE US

TABLE 26: KEY MARKET FORECAST ASSUMPTION OF EWING SARCOMA IN EU4 AND THE UK

TABLE 27: KEY MARKET FORECAST ASSUMPTION OF EWING SARCOMA IN JAPAN

TABLE 28: TOTAL MARKET SIZE OF EWING SARCOMA IN THE 7MM, USD MILLION (2019-2032)

TABLE 29: MARKET SIZE OF EWING SARCOMA BY THERAPIES IN THE 7MM, USD MILLION (2019-2032)

TABLE 30: TOTAL MARKET SIZE OF EWING SARCOMA IN THE US, USD MILLION (2019-2032)

TABLE 31: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN THE US, USD MILLION (2019-2032)

TABLE 32: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE THERAPIES IN THE US, USD MILLION (2019-2032)

TABLE 33: TOTAL MARKET SIZE OF EWING SARCOMA IN EU4 AND THE UK, USD MILLION (2019-2032)

TABLE 34: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN EU4 AND THE UK, USD MILLION (2019-2032)

TABLE 35: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE THERAPIES IN EU4 AND THE UK, USD MILLION (2019-2032)

TABLE 36: TOTAL MARKET SIZE OF EWING SARCOMA IN JAPAN, USD MILLION (2019-2032)

TABLE 37: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN JAPAN, USD MILLION (2019-2032)

TABLE 38: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE THERAPIES IN JAPAN, USD MILLION (2019-2032)

List of Figures

FIGURE 1: SYMPTOMS OF EWING SARCOMA

FIGURE 2: TREATMENT ALGORITHM OF EWING SARCOMA

FIGURE 3: CURRENT TREATMENT ALGORITHM OF LOCALIZED EWING SARCOMA

FIGURE 4: CURRENT TREATMENT ALGORITHM OF METASTATIC EWING SARCOMA

FIGURE 5: NCCN RECOMMENDATION FOR EWING SARCOMA

FIGURE 6: NCCN RECOMMENDATION FOR EWING SARCOMA

FIGURE 7: NCCN GUIDELINE

FIGURE 8: TOTAL INCIDENT CASES OF EWING SARCOMA IN THE 7MM (2019-2032)

FIGURE 9: TOTAL INCIDENT CASES OF EWING SARCOMA IN THE US (2019-2032)

FIGURE 10: AGE-SPECIFIC CASES OF EWING SARCOMA IN THE US (2019-2032)

FIGURE 11: GENDER-SPECIFIC CASES OF EWING SARCOMA IN THE US (2019-2032)

FIGURE 12: STAGE-SPECIFIC CASES OF EWING SARCOMA IN THE US (2019-2032)

FIGURE 13: TOTAL INCIDENT CASES OF EWING SARCOMA IN EU4 AND THE UK (2019-2032)

FIGURE 14: AGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2019-2032)

FIGURE 15: GENDER-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2019-2032)

FIGURE 16: STAGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK (2019-2032)

FIGURE 17: TOTAL INCIDENT CASES OF EWING SARCOMA IN JAPAN (2019-2032)

FIGURE 18: AGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2019-2032)

FIGURE 19: GENDER-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2019-2032)

FIGURE 20: STAGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN (2019-2032)

FIGURE 21: TOTAL MARKET SIZE OF EWING SARCOMA IN THE 7MM, USD MILLION (2019-2032)

FIGURE 22: MARKET SIZE OF EWING SARCOMA BY THERAPIES IN THE 7MM, USD MILLION (2019-2032)

FIGURE 23: TOTAL MARKET SIZE OF EWING SARCOMA IN THE US, USD MILLION (2019-2032)

FIGURE 24: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN THE US, USD MILLION (2019-2032)

FIGURE 25: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN THE US, USD MILLION (2019-2032)

FIGURE 26: TOTAL MARKET SIZE OF EWING SARCOMA IN EU4 AND THE UK, USD MILLION (2019-2032)

FIGURE 27: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN EU4 AND THE UK, USD MILLION (2019-2032)

FIGURE 28: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN THE EU4 AND THE UK, USD MILLION (2019-2032)

FIGURE 29: TOTAL MARKET SIZE OF EWING SARCOMA IN JAPAN, USD MILLION (2019-2032)

FIGURE 30: MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN JAPAN, USD MILLION (2019-2032)

FIGURE 31: MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN JAPAN, USD MILLION (2019-2032)

FIGURE 32: UNMET NEEDS

FIGURE 33: HEALTH TECHNOLOGY ASSESSMENT

FIGURE 34: REIMBURSEMENT PROCESS IN GERMANY

FIGURE 35: REIMBURSEMENT PROCESS IN FRANCE

FIGURE 36: REIMBURSEMENT PROCESS IN ITALY

FIGURE 37: REIMBURSEMENT PROCESS IN SPAIN

FIGURE 38: REIMBURSEMENT PROCESS IN THE UNITED KINGDOM

FIGURE 39: REIMBURSEMENT PROCESS IN JAPAN

FIGURE 40: TREATMENT PAYOR STATUS FOR BONES AND JOINTS CANCERS IN THE UNITED STATES (2004-2015)

Key Highlights:

• More than 80% of incident cases were observed in below 18 years old and only 20% of the cases were found in adults.
• A molecular-targeted therapy with minimal risk of late toxicities would be beneficial because the majority of Ewing sarcoma patients are under 20 years old.
• There are no standardized second-line treatment plans for relapsed or refractory Ewing sarcoma. Considerations need to be made depending on the site(s) of disease recurrence and prior therapy.
• The adoption of the VDC/IE regimen has significantly increased survival. Patients with metastatic ES continue to experience negative outcomes, which will increase the demand for future therapeutics.
• The prognosis for Ewing sarcoma has improved over the years due to advances in treatment. The five-year survival rate for localized Ewing sarcoma is around 70-80%, while the survival rate for metastatic disease is lower, around 30-40%. However, it's important to note that survival rates can vary depending on individual factors and the response to treatment.
• In the updated version 2.2023 of the NCCN guidelines lurbinectedin has been added as a second-line therapy option for Ewing sarcoma (for R/R or metastatic disease). Under category 2B, this is useful in certain circumstances recommendation.
• Since no therapies are approved for Ewing sarcoma, there is a significant market opportunity for the companies to enter this space and get the first-mover advantage
• In 2022, the US accounted for the maximum share of the total market in the 7MM, i.e., 53%, followed by EU4 and the UK.
• The usage of off-label therapies may hamper the uptake of new therapies
• Due to a potential unexpected significant adverse reaction (SUSAR), Salarius voluntarily stopped enrolling new patients in its Phase I/II trial of seclidemstat as a therapy for Ewing sarcoma last year. The FDA ended its examination of the company's application for seclidemstat in May 2023 and declared that the clinical trial might be restarted.

DelveInsight's "Ewing Sarcoma - Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Ewing Sarcoma, historical and forecasted epidemiology as well as Ewing Sarcoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Ewing Sarcoma market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Ewing Sarcoma market size from 2019 to 2032. The report also covers current Ewing Sarcoma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Ewing Sarcoma Disease Understanding and Treatment Algorithm

Ewing Sarcoma Overview:

Ewing Sarcoma

Ewing sarcoma (also known as Ewing's sarcoma) is a cancerous tumor that usually begins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. Although Ewing's sarcoma can develop in any bone, it usually affects the long bones, such as the thighbone (femur), shinbone (tibia), and upper arm bone (humerus). The bones of the pelvis are also often affected. Occasionally, the tumor begins in the muscles and soft tissues. The most common symptoms are stiffness, pain, swelling, or tenderness in the bone or the tissue surrounding the bone.

Ewing Sarcoma Diagnosis

The patient's journey begins with symptoms such as persistent bone pain even at rest, swelling, and a large palpable mass on the affected bone. Followed by a visit to the orthopedist, where the patient is suggested diagnostic tests such as MRI, CT scan, and plain radiography. After the diagnosis patient is referred to an oncologist for further treatment. A tissue biopsy is performed of the mass removed from the most aggressive portion of the cancer as determined by imaging for confirmatory diagnosis. Once Ewing Sarcoma is confirmed, relevant treatment is given to the patient.

Further details related to diagnosis are provided in the report…

Ewing Sarcoma Treatment

The treatment of Ewing sarcoma typically involves a multidisciplinary approach, including surgery, chemotherapy, and radiation therapy. NCCN recommended different chemotherapy combinations for the treatment of localized and metastatic Ewing sarcoma. VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide), VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin), and VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) are recommended by NCCN in the first line and as primary therapy for metastatic disease at initial presentation. For second-line treatment Cyclophosphamide and topotecan, Irinotecan + temozolomide ±

Vincristine, Ifosfamide, carboplatin, etoposide, and Lurbinectedin are recommended by NCCN.

Ewing Sarcoma Epidemiology

As the market is derived using a patient-based model, the Ewing Sarcoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Ewing Sarcoma, gender-specific cases of Ewing Sarcoma, age-specific cases of Ewing Sarcoma, stage-specific cases of Ewing Sarcoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032. The total incident cases of Ewing sarcoma in the 7MM comprised approximately 1,250 cases in 2022 and are projected to increase during the forecasted period.

• In the 7MM the highest incident cases of Ewing Sarcoma were seen in the United States, followed by EU4 and the UK.
• Among the EU4, Germany accounted for the highest number of Ewing sarcoma cases, followed by France, whereas Italy accounted for the lowest cases.
• In age-specific cases of Ewing sarcoma in 2022, the maximum number of cases were observed in 10-14 years of age group.
• Males than females are more likely to get Ewing Sarcoma. In the United States in 2022, ~300 incident cases of male Ewing Sarcoma were found.

Ewing Sarcoma Drug Chapters

The drug chapter segment of the Ewing Sarcoma report encloses a detailed analysis of the Ewing Sarcoma late-stage (Phase II) pipeline drug. There are currently no approved therapies for Ewing Sarcoma. It also helps understand the Ewing Sarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Emerging Drug

Seclidemstat: Salarius Pharmaceuticals

Seclidemstat (SP-2577) inhibits LSD1's enzymatic activity and its scaffolding function. SP-2577 is being studied in an ongoing Phase I/II trial in Ewing sarcoma. Salarius is studying the combination of SP-2577 with topotecan and cyclophosphamide (TC), two agents that are commonly given as second or third-line therapy, to improve patient outcomes over TC alone. In October 2022, the company voluntarily paused new patient enrollment in its Phase I/II trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas per protocol design. The pause in new patient enrollment was due to a metastatic FET-rearranged sarcoma patient death classified as a suspected unexpected serious adverse reaction (SUSAR). Later on May 5, 2023, the company was notified by FDA that they had completed the review of the company's submission and had concluded that the clinical trial may be resumed. The Company plans to restart enrollment of Phase I/II trial and anticipate data update by 2H 2023 and also plans to meet with FDA to discuss future development and potential registration pathways for SP-2577.

ZEPZELCA (lurbinectedin): Jazz Pharmaceuticals and PharmaMar

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. In December 2019, PharmaMar and Jazz Pharmaceuticals announced that PharmaMar and Jazz Pharmaceuticals had entered into an exclusive license agreement for lurbinectedin in the United States. In the updated version 2.2023 of the NCCN guidelines lurbinectedin has been added as a second-line therapy option for Ewing sarcoma (for R/R or metastatic disease). Under category 2B this is useful in certain circumstances recommendation

Note: Detailed emerging therapies assessment will be provided in the final report.

Drug Class Insights

CDK inhibitors: Proteins involved in RNA transcription, processing, and translation, such as CDK9, CDK12, and CDK13, have shown preclinical promise either alone or in combination with oncoprotein or growth factor targeting, with ongoing trials. Furthermore, CDK4 and CDK6, cell cycle proteins with different functions, have been identified as potential targets unrelated to the fusion oncoprotein in several screens. Trials testing CDK4 and CDK6 inhibitors combined with relapsed Ewing sarcoma chemotherapy regimens are underway.

The upcoming treatment landscape is poised to expand further after new classes, such as tetravalent death receptor 5 (DR5) agonist antibodies, CDK inhibitors, LSD1 inhibitors, AXL inhibitors, and others. Designed to overcome the limitations of earlier-generation agonists and exploit the tumor-specific cell death induced by DR5 activation. DR5 is one of two pro-apoptotic receptors for the trimeric tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Ewing Sarcoma Market Outlook

While advancements in the treatment of Ewing Sarcoma, such as chemotherapy and surgical procedures along with radiation therapy, have resulted in better survival rates for some patients, progress has been stagnant for others. The management of high-risk Ewing Sarcoma and other related sarcomas remains controversial, primarily due to an incomplete understanding of their high-risk biological characteristics and relatively low occurrence. These factors have made it challenging to conduct comprehensive clinical trials for the smaller populations of high-risk Ewing Sarcoma patients and the rarer subtypes of sarcomas.

Although there is no standardized second-line treatment for refractory or relapsed Ewing sarcoma, several retrospective studies have reported on conventional salvage treatments. Common salvage regimens involve topotecan, cyclophosphamide, irinotecan, temozolomide, or high-dose chemotherapy (HDC) followed by reinfusion of hematopoietic stem cells.

The current market has been based on the prevailing treatment pattern across the 7MM, which presents minor variations in the overall prescription pattern. Chemotherapy, radiation, surgery, and others are the current treatment options in the forecast model.

The expected launch of upcoming therapy and greater integration of early patient screening, medication in secondary care and other clinical settings, research on best methods for implementation, and an upsurge in awareness will eventually facilitate the development of effective treatment options. However, since Ewing Sarcoma is an orphan disease, it is difficult to conduct clinical trials. The meager outcome data for locally advanced or metastatic patients indicate that new treatment options are needed. For the Phase I trials, it is difficult to conclude because of the low numbers of Ewing Sarcoma enrolled and at different dose levels. Some Phase II trials show promising results, which support further research. Retrospective studies are encouraged as they could add to the limited data available. Efforts to increase the number of studies on this orphan disease are urgently needed.

• The total market size of Ewing Sarcoma in the 7MM is approximately USD 26 million in 2022 and is projected to increase during the forecast period (2023-2032).
• Among EU4 countries, Germany accounts for the maximum market size in 2022, while Italy occupies the bottom of the ladder.
• In Japan, Seclidemstat + TC is expected to capture the highest market share among emerging therapies in the 2L+ setting.
• The introduction of novel treatment options, including targeted therapies, immunotherapies, and combination regimens, will expand the treatment landscape for Ewing sarcoma to improve survival rates and reduce the side effects associated with traditional treatments like chemotherapy and radiation therapy.
• The majority of therapies that are being evaluated for Ewing Sarcoma are in the early phase of development. Key players developing a treatment for Ewing Sarcoma are Salarius Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, BioAlta, Inhibrx, and others.

Ewing Sarcoma Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2019-2032. In Ewing Sarcoma, Salarius Pharmaceuticals is developing Seclidemstat, with a fast uptake, with a probability-adjusted peak share of 42% in the second line and above setting in the US.

Further detailed analysis of emerging therapies drug uptake in the report…

Ewing Sarcoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Ewing Sarcoma's emerging therapy.

KOL Views:

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Ewing Sarcoma evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers; Medical Oncologists; Orthopedists, and Professors; MD, FACS, Chair of the Department of Orthopedic Surgery, and professor at UC Davis Comprehensive Cancer Center in Sacramento, California; MD, Director, Sarcoma Oncology Center, California; and others.

DelveInsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Sarcoma Oncology Center, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Ewing Sarcoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

The analyst views analyze multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in Ewing Sarcoma trials, progression-free survival is one of the most important primary outcome measures.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers' concerns about budget impact. The high cost of rare disease drugs usually has a limited effect on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently. Overall, treatment for bone and joint cancers can easily exceed USD 100,000 for a single patient. This is particularly true if a patient receives surgery, chemotherapy, and radiation therapy. The cost will be much higher if one includes bone-replacing endoprostheses or artificial limbs used in cases requiring amputation.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Ewing Sarcoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current treatment landscape.
• A detailed review of the Ewing Sarcoma market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Ewing Sarcoma market.

Ewing Sarcoma Report Insights

• Patient Population
• Therapeutic Approaches
• Ewing Sarcoma Pipeline Analysis
• Ewing Sarcoma Market Size and Trends
• Existing and future Market Opportunity

Ewing Sarcoma Report Key Strengths

• Ten Years Forecast
• 7MM Coverage
• Ewing Sarcoma Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Ewing Sarcoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Analyst Views)

Key Questions:

Market Insights

• What was the Ewing Sarcoma total market size, the market size by therapies, market share (%) distribution in 2019, and what would it look like in 2032? What are the contributing factors for this growth?
• What will be the impact of Seclidemstat's expected approval in 2025?
• How would CDK inhibitors perform as a class in the second line?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Ewing Sarcoma? What will be the growth opportunities across the 7MM concerning the patient population with Ewing Sarcoma?
• What is the historical and forecasted Ewing Sarcoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear with symptoms? Why is the current year diagnosis rate not high?
• Which gender has a higher incidence of Ewing Sarcoma?
• Which age group of Ewing Sarcoma has a high patient share?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Ewing Sarcoma? What are the current guidelines for treating Ewing Sarcoma in the US and Europe?
• How many companies are developing therapies for the treatment of Ewing Sarcoma?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Ewing Sarcoma?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What key designations have been granted for the emerging therapies for Ewing Sarcoma?
• What is the cost burden of current therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, current therapies? Focusing on the reimbursement policies.
• What is the 7MM historical and forecasted market of Ewing Sarcoma?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Ewing Sarcoma market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Analyst view section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY OF EWING SARCOMA

4. KEY EVENTS

5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

6. EWING SARCOMA MARKET OVERVIEW AT A GLANCE

• 6.1. MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN 2019
• 6.2. MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN 2032

7. DISEASE BACKGROUND AND OVERVIEW

• 7.1. INTRODUCTION
• 7.2. CAUSES
• 7.3. SIGNS AND SYMPTOMS
• 7.4. STAGING
  • 7.4.1. THE TNM SYSTEM
• 7.5. RISK FACTORS
• 7.6. PATHOLOGICAL DIAGNOSIS
• 7.7. DIAGNOSTIC TESTS
  • 7.7.1. IMAGING TESTS
  • 7.7.2. SURGICAL TESTS
  • 7.7.3. OTHER LABORATORY TESTS

8. TREATMENT MANAGEMENT OF EWING SARCOMA

• 8.1.1. TREATMENT ALGORITHM

9. TREATMENT GUIDELINES FOR EWING SARCOMA

• 9.1. NCCN GUIDELINES: 2023
• 9.2. EWING SARCOMA: ESMO-PAEDCAN-EURACAN CLINICAL PRACTICE GUIDELINES FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP
• 9.3. JAPAN GUIDELINE

10. EPIDEMIOLOGY AND PATIENT POPULATION

• 10.1. KEY FINDINGS
• 10.2. ASSUMPTIONS AND RATIONALE
• 10.3. TOTAL INCIDENT CASES OF EWING SARCOMA IN THE 7MM
• 10.4. THE UNITED STATES
  • 10.4.1. TOTAL INCIDENT CASES OF EWING SARCOMA IN THE UNITED STATES
  • 10.4.2. AGE-SPECIFIC CASES OF EWING SARCOMA IN THE UNITED STATES
  • 10.4.3. GENDER-SPECIFIC CASES OF EWING SARCOMA IN THE UNITED STATES
  • 10.4.4. STAGE-SPECIFIC CASES OF EWING SARCOMA IN THE UNITED STATES
• 10.5. EU4 AND THE UK
  • 10.5.1. TOTAL INCIDENT CASES OF EWING SARCOMA IN EU4 AND THE UK
  • 10.5.2. AGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK
  • 10.5.3. GENDER-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK
  • 10.5.4. STAGE-SPECIFIC CASES OF EWING SARCOMA IN EU4 AND THE UK
• 10.6. JAPAN
  • 10.6.1. TOTAL INCIDENT CASES OF EWING SARCOMA IN JAPAN
  • 10.6.2. AGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN
  • 10.6.3. GENDER-SPECIFIC CASES OF EWING SARCOMA IN JAPAN
  • 10.6.4. STAGE-SPECIFIC CASES OF EWING SARCOMA IN JAPAN

11. PATIENT JOURNEY

12. KEY ENDPOINTS IN EWING SARCOMA

13. EMERGING DRUGS

• 13.1. KEY COMPETITORS
• 13.2. SECLIDEMSTAT (SP-2577): SALARIUS PHARMACEUTICALS
  • 13.2.1. PRODUCT DESCRIPTION
  • 13.2.2. OTHER DEVELOPMENT ACTIVITIES
  • 13.2.3. CLINICAL DEVELOPMENT
    • 13.2.3.1. CLINICAL TRIALS INFORMATION
  • 13.2.4. SAFETY AND EFFICACY
• 13.3. ZEPZELCA (LURBINECTEDIN): JAZZ PHARMACEUTICALS AND PHARMAMAR
  • 13.3.1. PRODUCT DESCRIPTION
  • 13.3.2. OTHER DEVELOPMENT ACTIVITIES
  • 13.3.3. CLINICAL DEVELOPMENT
    • 13.3.3.1. CLINICAL TRIALS INFORMATION
  • 13.3.4. SAFETY AND EFFICACY
• 13.4. VERZENIO (ABEMACICLIB): ELI LILLY
  • 13.4.1. PRODUCT DESCRIPTION
  • 13.4.2. CLINICAL DEVELOPMENT
    • 13.4.2.1. CLINICAL TRIALS INFORMATION
• 13.5. IBRANCE (PALBOCICLIB): PFIZER
  • 13.5.1. PRODUCT DESCRIPTION
  • 13.5.2. CLINICAL DEVELOPMENT
    • 13.5.2.1. CLINICAL TRIALS INFORMATION
• 13.6. MECBOTAMAB VEDOTIN (BA3011): BIOATLA
  • 13.6.1. PRODUCT DESCRIPTION
  • 13.6.2. OTHER DEVELOPMENT ACTIVITIES
  • 13.6.3. CLINICAL DEVELOPMENT
    • 13.6.3.1. CLINICAL TRIALS INFORMATION
• 13.7. IOPOFOSINE I 131 (CLR 131): CELLECTAR BIOSCIENCES
  • 13.7.1. PRODUCT DESCRIPTION
  • 13.7.2. OTHER DEVELOPMENT ACTIVITIES
  • 13.7.3. CLINICAL DEVELOPMENT
    • 13.7.3.1. CLINICAL TRIALS INFORMATION
• 13.8. TP-1287: SUMITOMO PHARMA ONCOLOGY
  • 13.8.1. PRODUCT DESCRIPTION
  • 13.8.2. OTHER DEVELOPMENT ACTIVITIES
  • 13.8.3. CLINICAL DEVELOPMENT
    • 13.8.3.1. CLINICAL TRIALS INFORMATION
• 13.9. INBRX-109: INHIBRX
  • 13.9.1. PRODUCT DESCRIPTION
  • 13.9.2. CLINICAL DEVELOPMENT
    • 13.9.2.1. CLINICAL TRIALS INFORMATION

14. EWING SARCOMA: 7MM MARKET ANALYSIS

• 14.1. KEY FINDINGS
• 14.2. MARKET OUTLOOK
• 14.3. KEY MARKET FORECAST ASSUMPTIONS
• 14.4. CONJOINT ANALYSIS
• 14.5. TOTAL MARKET SIZE OF EWING SARCOMA IN THE 7MM
• 14.6. MARKET SIZE OF EWING SARCOMA BY THERAPIES IN THE 7MM
• 14.7. UNITED STATES MARKET SIZE
  • 14.7.1. TOTAL MARKET SIZE OF EWING SARCOMA IN THE UNITED STATES
  • 14.7.2. MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN THE UNITED STATES
  • 14.7.3. MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN THE UNITED STATES
• 14.8. EU4 AND THE UK MARKET SIZE
  • 14.8.1. TOTAL MARKET SIZE OF EWING SARCOMA IN EU4 AND THE UK
  • 14.8.2. MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN EU4 AND THE UK
  • 14.8.3. MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN EU4 AND THE UK
• 14.9. JAPAN MARKET SIZE
  • 14.9.1. TOTAL MARKET SIZE OF EWING SARCOMA IN JAPAN
  • 14.9.2. MARKET SIZE OF EWING SARCOMA BY FIRST-LINE THERAPIES IN JAPAN
  • 14.9.3. MARKET SIZE OF EWING SARCOMA BY SECOND-LINE AND ABOVE THERAPIES IN JAPAN

15. UNMET NEEDS

16. SWOT ANALYSIS

17. KOL VIEWS

18. MARKET ACCESS AND REIMBURSEMENT

• 18.1. UNITED STATES
  • 18.1.1. CENTRE FOR MEDICARE & MEDICAID SERVICES (CMS)
• 18.2. EU4 AND THE UK
  • 18.2.1. GERMANY
  • 18.2.2. FRANCE
  • 18.2.3. ITALY
  • 18.2.4. SPAIN
  • 18.2.5. UNITED KINGDOM
• 18.3. JAPAN
  • 18.3.1. MHLW
• 18.4. ECONOMIC BURDEN OF MALIGNANT BONE TUMORS AND SARCOMAS

19. APPENDIX

• 19.1. BIBLIOGRAPHY
• 19.2. REPORT METHODOLOGY

20. DELVEINSIGHT CAPABILITIES

21. DISCLAIMER